Prasugrel: A review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention

Drugs

Volumn 69, Issue 12, 2009, Pages 1707-1726

  Duggan, Sean T ^a,b   Keating, Gillian M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Acute coronary syndromes; Pharmacodynamics; Pharmacokinetics; Prasugrel; Therapeutic use; Tolerability

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; AMFEBUTAMONE; ATORVASTATIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOPIDOGREL; CYTOCHROME P450; DIGOXIN; DILTIAZEM; DRUG METABOLITE; EFIENT; HEPARIN; INDINAVIR; KETOCONAZOLE; LANSOPRAZOLE; PRASUGREL; PRODRUG; PURINERGIC P2Y12 RECEPTOR; R 138727; RANITIDINE; RIFAMPICIN; TELITHROMYCIN; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ACUTE CORONARY SYNDROME; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BACKACHE; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; COLON TUMOR; CORONARY ARTERY BYPASS GRAFT; CORONARY STENT; DEATH; DIABETES MELLITUS; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; FOLLOW UP; HEADACHE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INCIDENCE; LOADING DRUG DOSE; NEUTROPENIA; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; RECOMMENDED DRUG DOSE; RECURRENT DISEASE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; BLOOD LOSS, SURGICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOPHENES; TICLOPIDINE; TISSUE DISTRIBUTION; YOUNG ADULT;

ANGINA;

EID: 68949171927     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/10484190-000000000-00000     Document Type: Review

References (71)

1. Jennings LK. Role of platelets in atherothrombosis. Am J Cardiol 2009 Feb 2; 103 (3 Suppl.): 4-10A
2. Meadows TA, Bhatt DL. Clinical aspects of platelet inhibitors and thrombus formation. Circ Res 2007; 100 (9): 1261-75
3. Steinhubl SR, Moliterno DJ. The role of the platelet in the pathogenesis of atherothrombosis. Am J Cardiovasc Drug 2005; 5 (6): 399-408
4. Wilson JM, Ferguson 3rd JJ. Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications. Clin Cardiol 1999 Nov; 22 (11): 687-98
5. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007 Jul; 28 (13): 1598-660
6. Sanz-Ruiz R, Fernandez-Aviles F. European perspective on the use of antiplatelet agents in atherothrombotic disease. Eur Heart J Suppls 2008; 10 Suppl. I: I14-8
7. Angiolillo DJ. ADP receptor antagonism: what's in the pipeline? Am J Cardiovasc Drugs 2007; 7 (6): 423-32
8. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2007 Aug 14; 116 (7): e148-304
9. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008 Jan 15; 117 (2): 296-329
10. King 3rd SB, Smith Jr SC, Hirshfeld Jr JW, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008 Jan 15; 117 (2): 261-95
11. Silber S, Albertsson P, Aviles FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005 Apr; 26 (8): 804-47
12. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007 Apr 10; 49 (14): 1505-16
13. Bates ER, Lau WC, Bleske BE. Loading, pretreatment, and interindividual variability issues with clopidogrel dosing. Circulation 2005 May 24; 111 (20): 2557-9
14. Angiolillo DJ, Guzman LA, Bass TA. Current antiplatelet therapies: benefits and limitations. Am Heart J 2008 Aug; 156 (2 Suppl.): S3-9
15. Fuster V, Farkouh ME. Acute coronary syndromes and diabetes mellitus: a winning ticket for prasugrel. Circulation 2008 Oct 14; 118 (16): 1607-8
16. Hasegawa M, Sugidachi A, Ogawa T, et al. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor. Thromb Haemost 2005 Sep; 94 (3): 593-8
17. Algaier I, Jakubowski JA, Asai F, et al. Interaction of the active metabolite of prasugrel, R-138727, with the residues cysteine97 and cysteine175 of the human P2Y(12)-receptor. J Thromb Haemost 2008; 6 (11): 1908-14
18. Sugidachi A, Ogawa T, Kurihara A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's activemetabolite. J ThrombHaemost 2007 Jul; 5 (7): 1545-51
19. Niitsu Y, Sugidachi A, Ogawa T, et al. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species. Eur J Pharmacol 2008 Jan 28; 579 (1-3): 276-82
20. Asai F, Jakubowski JA,NaganumaH, et al. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: a single ascending dose study in healthy humans. Platelets 2006 Jun; 17 (4): 209-17
21. Jakubowski JA, Matsushima N, Asai F, et al. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans. Br J Clin Pharmacol 2007 Apr; 63 (4): 421-30
22. Jakubowski JA, Payne CD, Weerakkody GJ, et al. Dosedependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects. J Cardiovasc Pharmacol 2007 Mar; 49 (3): 167-73
23. Brandt JT, Payne CD, Wiviott SD, et al. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.AmHeart J 2007 Jan; 153 (1): 66.e9-16
24. Jernberg T, Payne CD, Winters KJ, et al. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirintreated patients with stable coronary artery disease. Eur Heart J 2006 May; 27 (10): 1166-73
25. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 2008 Jan; 29 (1): 21-30
26. Erlinge D, Varenhorst C, Braun OO, et al. Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo. JAmColl Cardiol 2008 Dec 9; 52 (24): 1968-77
27. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregationthrombolysis in myocardial infarction 44 trial. Circulation 2007 Dec 18; 116 (25): 2923-32
28. Farid NA, Smith RL, Gillespie TA, et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007 Jul; 35 (7): 1096-104
29. Rehmel JL, Eckstein JA, Farid NA, et al. Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450. Drug Metab Dispos 2006 Apr; 34 (4): 600-7
30. Sanofi-Aventis. Plavix (75mg & 300mg film coated tablets) summary of product characteristics [online]. Available from URL: http://emc.medicines.org. uk/medicine/9483/SPC/Plavix+(sanofi-aventis)/ [Accessed 2009 Jun 12]
31. Eli Lilly and Company Limited. Efient (5mg & 10mg film coated tablets) summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/medicine/21504/SPC/Efient+5mg+& +10mg+film+coated+tablets/ [Accessed 2009 Mar 16]
32. Payne CD, Li YG, Small DS, et al. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol 2007 Nov; 50 (5): 555-62
33. European Medicines Agency. Assessment report for Efient [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Efient/H-984- en6.pdf [Accessed 2009 Jun 15]
34. Williams ET, Jones KO, Ponsler GD, et al. The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos 2008 Mar 27; 36 (7): 1227-32
35. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel. Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.Circulation 2009May 19; 119 (19): 2553-60
36. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007 Dec; 5 (12): 2429-36
37. Small DS, Kothare PA, Yuen ES, et al. The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects [abstract no. PII-47]. Clin Pharmacol Ther 2008; 83 Suppl. 1: S56-7
38. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007 Nov 15; 357 (20): 2001-15
39. Small DS, Farid NA, Li YG, et al. Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. Curr Med Res Opin 2008 Aug; 24 (8): 2251-7
40. Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol 2008 Apr; 48 (4): 475-84
41. Farid NA, Payne CD, Small DS, et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81 (5): 735-41
42. Wiviott SD, Antman EM, Gibson CM, et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J 2006 Oct; 152 (4): 627-35
43. Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005 Jun 28; 111 (25): 3366-73
44. Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes. A report of the American College of Cardiology task force on clinical data standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001 Dec; 38 (7): 2114-30
45. Antman EM, Wiviott SD, Murphy SA, et al. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitioN with prasugrel- Thrombolysis In Myocardial Infarction) analysis. J Am Coll Cardiol 2008 May 27; 51 (21): 2028-33
46. Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009 Feb 28; 373 (9665): 723-31
47. Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008 Apr 19; 371 (9621): 1353-63
48. Wiviott SD, Braunwald E,AngiolilloDJ, et al.Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38. Circulation 2008 Oct 14; 118 (16): 1626-36
49. Murphy SA, Antman EM, Wiviott SD, et al. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur Heart J 2008 Oct; 29 (20): 2473-9
50. Morrow DA, Wiviott SD, White HD. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel: thrombolysis in myocardial infarction 38 an application of the classification system from the universal definition of myocardial infarction. Circulation 2009 Jun; 119 (21): 2758-64
51. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial infarction. Eur Heart J 2007 Oct; 28 (20): 2525-38
52. Salazar DE, Ernest CS, Wrishko RE, et al. Relationship between exposure to the prasugrel active metabolite with TIMI major/minor bleeding in TRITON-TIMI 38 [abstract no. 4001]. Circulation 2008 Oct; 118 Suppl. 2: S815
53. Dalby AJ, Wiviott SD, Murphy SA, et al. The Influence of the arterial access site and its management on bleeding events in acute coronary syndromes in TRITON - TIMI 38. Circulation 2008 Oct; 118 Suppl. 2: S638
54. Wiviott SD, Ruff CT, Antman EM, et al. Regional safety and efficacy of prasugrel compared to clopidogrel: a TRITON-TIMI 38 analysis [abstract no. 4588]. Circulation 2008 Oct; 118 Suppl. 2: S917
55. Effient™ (prasugrel) [US prescribing information]. Indianapolis: Eli Lilly and Company, 2009 [online]. Available from URL: http://pi.lilly.com/ us/effient.pdf [Accessed 2009 Jul 13]
56. PloskerGL, Lyseng-WilliamsonKA. Clopidogrel: a reviewof its use in the prevention of thrombosis.Drugs 2007; 67 (4): 613-46
57. Eli Lilly and Company. European Commission approves Efient® (prasugrel) for patients with acute coronary syndrome undergoing PCI [media release]. 2009 Feb 23 [online]. Available from URL: http://newsroom.lilly.com/ releasedetail.cfm?ReleaseID=366955 [Accessed 2009 Apr 14]
58. Angiolillo DJ, Bhatt DL, Gurbel PA, et al. Advances in antiplatelet therapy: agents in clinical development. Am J Cardiol 2009 Feb 2; 103 (3 Suppl.): 40-51A
59. Niitsu Y, Jakubowski JA, Sugidachi A, et al. Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. Semin Thromb Hemost 2005 Apr; 31 (2): 184-94
60. Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 2009 Feb 2; 103 (3 Suppl.): 27-34A
61. Donahoe SM, Stewart GC, McCabe CH, et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007 Aug 15; 298 (7): 765-75
62. Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J 2008 Aug; 156 (2 Suppl.): S16-22
63. Bhatt DL. Intensifying platelet inhibition: navigating between Scylla and Charybdis. N Engl J Med 2007 Nov 15; 357 (20): 2078-81
64. Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebocontrolled trial. Lancet 2004 Jul 24; 364 (9431): 331-7
65. Serebruany VL. Platelet inhibition with prasugrel and increased cancer risks: potential causes and implications. Am J Med 2009 May; 122 (5): 407-8
66. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl JMed 2009 Jan 22; 360 (4): 354-62
67. Kaul S, Shah PK, Diamond GA, et al. Validity of the combined efficacy plus safety composite endpoint (net clinical benefit) in TRITON-TIMI 38 [abstract no. 4015]. Circulation 2008 Oct; 118 Suppl. 2: S819
68. Kaul S, Shah PK, Diamond GA. Weighted composite endpoint analysis of TRITON-TIMI 38: disconnect between analytical equivalence and clinical importance [abstract no. 4587]. Circulation 2008 Oct; 118 Suppl. 2: S916
69. Serebruany V, Shalito I, Kopyleva O. Prasugrel development: claims and achievements. Thromb Haemost 2009 Jan; 101 (1): 14-22
70. Hankey GJ, Eikelboom JW, Langton PE. Will prasugrel supersede clopidogrel for acute coronary syndromes? Med J Aust 2008 Apr 7; 188 (7): 381-2
71. Eli Lilly and Company. A comparison of prasugrel and clopidogrel in acute coronary syndrome subjects (TRILOGY ACS) [ClinicalTrials.gov identifier NCT00699998]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2009 Jun 17